In a report released today, Robert Wasserman from Benchmark Co. maintained a Buy rating on Nephros, with a price target of $5.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Robert Wasserman’s rating is based on Nephros’s impressive financial performance in the second quarter of 2025, where the company exceeded expectations with a significant increase in revenue and a shift to positive net income. The revenue growth was driven by strong programmatic sales and a substantial order in dialysis filtration, alongside an expansion in active user sites.
Additionally, Nephros has successfully launched new products and expanded its market reach beyond hospitals, contributing to its sales growth. The company also reported improved gross margins and a rise in adjusted EBITDA, strengthening its cash position with no long-term debt. These factors, combined with anticipated revenue growth, support the maintained Speculative Buy rating and a price target that suggests potential price appreciation.
In another report released on August 8, Maxim Group also maintained a Buy rating on the stock with a $6.00 price target.